Clinical Trials Logo

GIST, Malignant clinical trials

View clinical trials related to GIST, Malignant.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04879979 Recruiting - CBT Clinical Trials

GIST and Memory and Attention Adaptation Training

GIST-MAAT
Start date: January 12, 2021
Phase: N/A
Study type: Interventional

Cognitive-behavioral therapy (CBT) has been found to be efficacious in the treatment of cancer-related cognitive impairment (CRCI). Memory and Attention Adaptation Training (MAAT) has been evaluated in previous clinical trials with samples of breast cancer survivors and found effective at reducing cancer-related cognitive impairment. MAAT has been demonstrated to be efficacious when it is delivered via videoconference.The use of telehealth delivery enhances access to cancer survivorship care and reduces time and travel burden among cancer survivors, especially those who live in rural and/or underserved areas where cancer survivor services are less available. People with a diagnosis of gastrointestinal stromal tumors also experience self-reported cancer-related cognitive impairment. In order to determine if MAAT can sufficiently treat CRCI among people with gastrointestinal stromal tumors (GIST), we propose a trial of MAAT to determine its initial level of effectiveness in improving both self-reported cognitive impairments and objective neuropsychological test performance in GIST patients.

NCT ID: NCT03171389 Recruiting - GIST, Malignant Clinical Trials

POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

POETIG
Start date: March 22, 2017
Phase: Phase 2
Study type: Interventional

This is a non-randomized, open-label, multicenter phase 2 study to evaluate the efficacy and safety of ponatinib in patients with metastatic and/or unresectable GIST after prior failure or intolerability of imatinib. Patients will be enrolled into 1 of 2 cohorts based on absence (Cohort A) or presence (Cohort B) of KIT exon 13 resistance mutations as measured by liquid biopsy. A third cohort (Cohort C) will include patients who have received all approved lines of TKI treatments (imatinib, sunitinib and regorafenib).